MedPath

Influence of vitamin B6 on nausea (Nausea gravidarum)

Not Applicable
Recruiting
Conditions
O21.0
Mild hyperemesis gravidarum
Registration Number
DRKS00010769
Lead Sponsor
eibniz Universität Hannover, Institut für Lebensmittelwissenschaft und Humanernährung, Abteilung Ernährungsphysiologie und Humanernährung
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
150
Inclusion Criteria

Women with confirmed pregnancy to the end of the 10th week of pregnancy,
acute nausea during pregnancy (Nausea gravidarum)

Exclusion Criteria

deterioration of nausea gravidarium during the study period of two weeks;
intake of vitamin B6 supplements over 2 mg/day;

taking any medications against nausea and vomiting;
previous hospitalization due to nausea gravidarum;
BMI =30kg/m2;
Blood pressure: >160mmHg systolic or >100mmHg diastolic;
multiple pregnancy;
known complications in an earlier pregnancy (e.g. premature delivery, miscarriage, placental abnormalities, fetal anomaly);
severe chronic illness (manifest coronary heart disease, cancer);
insulin-dependent diabetes mellitus Typ I and II;

severe kidney or liver diseases;
conditions after gastrointestinal surgical procedure and chronic gastrointestinal diseases (especially small intestine e.g. duodenal ulcer, liver, pancreas), e.g. gastrectomy, celiac diseases, chronic pancreatitis, cholestasis, short bowel syndrome, chronic inflammatory bowel disease (except appendicitis, gallstone surgery);
hormonal disorders, for example, Cushing's syndrome and untreated hyperthyroidism;

addiction (alcohol, drugs and/or medications);
missing consent;
refusing / reset of the consent;
simultaneous participation in another clinical trial or participation within the last 30 days;
planned surgery within the next three month

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
nausea gravidarium measured by PUQE-Score (pregnancy-unique quantification of emesis and nausea) at the beginning of the study, during the study (daily for 14 days) and at the end of the study.
Secondary Outcome Measures
NameTimeMethod
nausea gravidarium measured by visual analogue scale at the beginning of the study, during the study (daily for 14 days) and at the end of the study. <br><br>Vitamin B6 plasma concentration at the beginning and end of the study. <br>
© Copyright 2025. All Rights Reserved by MedPath